Cure Genetics
PrivateLast Round
Series B
Jan 5, 2022
Total Funding Raised
$79.2M
Company Overview
Cure Genetics operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series B round in January 2022.
Cure Genetics is a biotechnology company that develops cell and gene therapies for solid tumors and genetic diseases using its proprietary AIMS CAR-NKT and VELP AAV platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cure Genetics Comparables
Compare Cure Genetics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EdiGene | 81% | |
| ImmunoKite Therapeutics | 77% | |
| Metagenomi | 76% |
For institutional investors. Book with your work email.
Cure Genetics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 5, 2022 | ||||
| Series A | Aug 6, 2018 | ||||
| Angel | Jan 1, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cure Genetics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oriza Holdings | Series B |
| Blue Ocean Capital Group | Series B |
| Advantech Capital | Series B |
| Qiming Venture Partners | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 6, 2018
$17M round led by Qiming Venture Partners
For institutional investors. Book with your work email.
Cure Genetics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cure Genetics's valuation, stock price, and market status.
Is Cure Genetics a public or private company?
Cure Genetics is a private company.
What is the current stock price of Cure Genetics?
Cure Genetics is a private company, so its shares have no public market price. Caplight tracks Cure Genetics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cure Genetics worth (valuation)?
Valuation information for Cure Genetics is not publicly available.
Can I buy Cure Genetics stock?
Cure Genetics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cure Genetics's last funding round?
Cure Genetics's most recent funding round was Series B on January 5, 2022.
Who are the main investors in Cure Genetics?
Key investors in Cure Genetics include Advantech Capital, Qiming Venture Partners.
Will Cure Genetics IPO soon?
No public IPO plans have been announced for Cure Genetics.
How can I track Cure Genetics secondary market activity?
Caplight tracks bids, offers, and trades in Cure Genetics's shares on secondary markets.